Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021

Rhea-AI Summary

Pacira BioSciences, Inc. (NASDAQ:PCRX) will release its first quarter financial results on May 4, 2021, before U.S. markets open. The company will host a live conference call at 8:30 a.m. ET to discuss these results. Interested parties can participate by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) with passcode 8238109. The call will be available for replay for one week. Pacira is known for its commitment to non-opioid pain management, notably through its long-acting analgesic EXPAREL® and the iovera°® cryoanalgesia device.

Positive

• Commitment to non-opioid pain management solutions.
• Commercial success of EXPAREL® since its launch in April 2012.
• Acquisition of the iovera°® system enhances product offerings.

Negative

• None.

PARSIPPANY, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Tuesday, May 4, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

To participate in the conference call, dial 1-877-845-0779 and provide the passcode 8238109. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.

For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 8238109. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

FAQ

When will Pacira BioSciences report its first quarter earnings for 2021?

Pacira BioSciences will report its first quarter earnings on May 4, 2021.

How can I participate in the Pacira BioSciences conference call?

You can participate by calling 1-877-845-0779 (domestic) or 1-720-545-0035 (international) with passcode 8238109.

What is EXPAREL® and when was it launched?

EXPAREL® is a long-acting local analgesic launched by Pacira in April 2012.

What technology does EXPAREL® use?

EXPAREL® utilizes DepoFoam®, a proprietary delivery technology for drug encapsulation.

What is the iovera°® system?

The iovera°® system is a handheld cryoanalgesia device acquired by Pacira that delivers controlled doses of cold temperature to targeted nerves.